Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Oxford BioDynamics
Oxford BioDynamics
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Pharmaceutical
Oxford BioDynamics appoints professor to its Scientific Advisory Board
Professor Iain McInnes will apply his expertise and insight as the company’s EpiSwitch technology continues to be adopted
Pharmaceutical
Oxford BioDynamics appoints new President for US subsidiary
Glen Ferguson has been made Senior VP of US at the parent company, but has also been appointed as the President of the new US subsidiary
Finance
Oxford BioDynamics signs fifth collaboration agreement in immuno-oncology space
The company will use its EpiSwitch platform to offer high resolution mapping of epigenetic profiles in patients
Pharmaceutical
Grant announcement of Canadian patent by Oxford BioDynamics
The now patented technology platform, EpiSwitch, enables the high resolution discovery and monitoring of regulatory conditional chromosome conformation signatures
Research & Development
OBD presents latest data on the use of EpiSwitch
EpiSwitch biomarkers have the potential to predict patient response to treatments with immune checkpoint inhibitors anti-PD-1 and anti-PD-L1
Research & Development
Collaboration identifies tool to predict response to rheumatoid arthritis therapy
Study published in Journal of <i>Translational Medicine</i> demonstrates predictive power of EpiSwitch to identify inadequate response to methotrexate in early rheumatoid arthritis
Pharmaceutical
Oxford BioDynamics appoint Paul Stockdale CFO
Subscribe now